68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin

Clinical Nuclear Medicine

Volumn 37, Issue 3, 2012, Pages 245-251

  Naswa, Niraj ^a   Sharma, Punit ^a   Kumar, Abhishek ^a   Soundararajan, Ramya ^a   Kumar, Rakesh ^a   Malhotra, Arun ^a   Ammini, Ariachery C ^a   Bal, Chandrashekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

68 Ga DOTANOC; CUP; NET; PET CT

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAI3 OCTREOTIDE GD 68; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; 68GA DOTANOC; 68GA-DOTANOC; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COLON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DUODENUM; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ILEUM; LUNG; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDGUT; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PANCREAS; PHYSICIAN; PRIMARY TUMOR; PROTEIN EXPRESSION; STOMACH; TUMOR LOCALIZATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 84857206195     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823ea730     Document Type: Article

References (19)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094-2103.
2. Altman E, Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer. 1986;57:120-124. (Pubitemid 16212245)
3. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005. (Pubitemid 37297755)
4. Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuro-endocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548-3554. (Pubitemid 46630525)
5. Nystrom S, Weiner JM, Wolf RM, et al. Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA. 1979;241:381-383. (Pubitemid 9221470)
6. Karsell PR, Sheedy PF II, O'Connell MJ. Computed tomography in search of cancer of unknown origin. JAMA. 1982;248:340-343. (Pubitemid 12070770)
7. Harewood GC, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol. 2002;97: 1386-1391. (Pubitemid 34664782)
8. Seve P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292-329.
9. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83. (Pubitemid 28107907)
10. Reubi J-C, Krenning E, Lamberts S, et al. Somatostatin receptors in malignant tissue. J Steroid Biochem Mol Biol. 1990;37:1073-1077.
11. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)-and (123ITyr3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20: 716-731. (Pubitemid 23284773)
12. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET-CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
13. Savelli G, Lucignani G, Seregni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero- pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25:445-449. (Pubitemid 38591104)
14. Prasad V, Ambrosini V, Hommann M, et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTANOC receptor PET-CT. Eur J Nucl Med Mol Imaging. 2010;37:67-77.
15. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generatorproduced 68Ga for medical application. J Nucl Med. 2007;48:1741-1748. (Pubitemid 47572722)
16. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita TV, Hellman S, Rosenberg SA, eds. Cancers, Principles and Practice of Oncology. 4th ed. Philadelphia, PA: Lippincott Co. 1997:2423-2443.
17. Regelink G, Brouwer J, de Bree R, et al. Detection of unknown primary tumors and metastases in patients with cervical metastases: value of FDGPET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002;29: 1024-1030.
18. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247. (Pubitemid 43817847)
19. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005;23:70-78. (Pubitemid 41702624)